FEMY (Femasys) Total Current Assets : $8.02 Mil (As of Dec. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Femasys Total Current Assets?

Total current assets includes Cash, Cash Equivalents, Marketable Securities, Total Receivables, Total Inventories, and Other Current Assets. Femasys's total current assets for the quarter that ended in Dec. 2024 was $8.02 Mil.

Femasys Total Current Assets Historical Data

The historical data trend for Femasys's Total Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Femasys Total Current Assets Chart

Femasys Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Total Current Assets

Get a 7-Day Free Trial

3.86

25.63

14.13

23.18

8.02

Femasys Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Total Current Assets	Get a 7-Day Free Trial															23.18	19.88	15.93	11.30	8.02

Femasys Total Current Assets Calculation

Total Current Assets are the asset that can be converted to cash or used to pay current liabilities within 12 months.

Femasys's Total Current Assets for the fiscal year that ended in Dec. 2024 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	3.452	+	0.488	+	3.046	+	1.036
	=	8.02

Femasys's Total Current Assets for the quarter that ended in Dec. 2024 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	3.452	+	0.488	+	3.046	+	1.036
	=	8.02

Total Current Assets is linked to the Current Ratio, which is the result of dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations.

Total Current Assets is also linked to Working Capital, Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Femasys (NAS:FEMY) Total Current Assets Explanation

In Ben Graham's calculation of liquidation value, inventory is only considered worth half of its book value, and accounts receivable is considered worth 75% of its value. Therefore the liquidation value is lower than calculated from total current assets.

Femasys's Liquidation Value for the quarter that ended in Dec. 2024 is

	Liquidation value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	3.452	-	10.141	+	0.75 * 0.488	+	0.5 * 3.046
=	-4.80

Femasys Total Current Assets Related Terms

Thank you for viewing the detailed overview of Femasys's Total Current Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Femasys Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Femasys Inc (NAS:FEMY) » Definitions » Total Current Assets

Comparable Companies

Traded in Other Exchanges

N/A

Address

3950 Johns Creek Court, Suite 100, Suwanee, GA, USA, 30024

Website

https://www.femasys.com

Femasys Inc is a biomedical company focused on transforming women's healthcare by developing solutions and advancements providing clinical impact to address severely underserved areas. The company's mission is to provide women with minimally invasive, non-surgical product technologies, accessible in the office, improving patient care and overall health economics. Its product portfolio includes FemaSeed Intratubal Insemination, an infertility treatment; FemVue, a companion diagnostic for fallopian tube assessment via ultrasound; FemBloc, a clinical product candidate being developed as a permanent birth control; FemCerv, a tissue sampler for cervical cancer diagnosis; and FemCath and FemChec. Geographically, it derives key revenue from the United States and rest from international markets.

Executives

Keith J Kendall	director	30 TECHNOLOGY DRIVE, WARREN NJ 07059
Alistair Milnes	director	C/O BICYCLE THERAPEUTICS PLC, B900, BABRAHAM RESEARCH CAMPUS, CAMBRIDGE X0 CB22 3AT
Christine E Thomas	officer: SVP, Regulatory & Clinical	2836 SW 117TH STREET, GAINESVILLE FL 32606
Dov Elefant	officer: Chief Financial Officer	EPICEPT CORPORATION, 270 SYLVAN AVENUE, ENGLEWOOD CLIFFS NJ 07632
Wendy Perrow	director	C/O BIOANALYTICAL SYSTEMS, INC., 2701 KENT AVENUE, WEST LAFAYETTE IN 47906
Edward Evantash	officer: Chief Medical Officer	3950 JOHNS CREEK COURT, SUITE 100, SUWANEE GA 30024
John Dyett	director, 10 percent owner	11111 SANTA MONICA BLVD., SUITE 2250, LOS ANGELES CA 90025
Adams John Q Jr	director	35 WYCK HILL LANE, WESTLAKE TX 76262
Edward R Uzialko	director, 10 percent owner	4605 DUDLEY LANE, ATLANTA GA 30327
Charles Larsen	director	28 SANDPIPER ROAD, TAMPA FL 33609
Kathy Lee-sepsick	director, officer: Chief Executive Officer	3950 JOHNS CREEK COURT, SUITE 100, SUWANEE GA 30024
Daniel Scott Currie	officer: Senior VP, Operations	3950 JOHNS CREEK COURT, SUITE 100, SUWANEE GA 30024
Kelley Hoskin Violet Alexandria	officer: VP, Clinical & Medical Affairs	3950 JOHNS CREEK COURT, SUITE 100, SUWANEE GA 30024
Gary Thompson	director	3950 JOHNS CREEK COURT, SUITE 100, SUWANEE GA 30024
William Benson Witte	director	11111 SANTA MONICA BLVD., SUITE 2250, LOS ANGELES CA 90025